Adaptive Biotechnologies Corp(ADPT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Adaptive Biotechnologies Corp (ADPT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ADPT at 41.4/100 on a 32-signal composite quality model, placing it at rank #2,063 of 2,962 stocks — the bottom half of the AI-ranked universe. ADPT scores in the top quartile across revenue growth (89.3), institutional flow (80.7). Areas of concern include balance sheet strength (16.2) and profitability (17.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 9.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Adaptive Biotechnologies Corp reports quarterly revenue of $71.6M, net income of $-39.8M, an operating margin of -22.0%. Top institutional holders of ADPT by reported 13-F value include VIKING GLOBAL INVESTORS, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ADPT trades on the Nasdaq exchange and files with the SEC under CIK 1478320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADPT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Adaptive Biotechnologies Corp directly from SEC EDGAR.